Source comparison
Does PT-141 Work for Sexual Response Research? (Comparison)
Site of action Central nervous system (hypothalamus MC4R receptors) Peripheral vasculature (corpus cavernosum smooth muscle) PT-141 is the only compound that acts centrally on arousal pathways. Making it mechanistically distinct Primary indication Female hypoa
This comparison does not assign a generated winner or score.
- Site of action
- Central nervous system (hypothalamus MC4R receptors)
- Peripheral vasculature (corpus cavernosum smooth muscle)
- PT-141 is the only compound that acts centrally on arousal pathways. Making it mechanistically distinct
- Primary indication
- Female hypoactive sexual desire disorder (HSDD)
- Male erectile dysfunction
- PT-141 addresses desire/arousal, not erectile function. Fundamentally different endpoints
- Onset of action
- 60–90 minutes
- 30–45 minutes
- 30–60 minutes
- Slower onset reflects CNS penetration and receptor cascade initiation
- Duration of effect
- 4–6 hours (behavioural), 2.7h half-life
- 4–6 hours
- 24–36 hours
- PT-141's effect duration doesn't match plasma half-life. Receptor occupancy persists longer
- FDA approval status
- Approved for premenopausal women with HSDD (2019)
- Approved for male ED (1998)
- Approved for male ED (2003)
- PT-141 is the only FDA-approved non-hormonal treatment for female sexual dysfunction
- Common side effects
- Nausea (40%), flushing (20%), headache (11%)
- Headache (16%), flushing (10%), dyspepsia (7%)
- Headache (15%), dyspepsia (11%), back pain (6%)
- PT-141's GI side effects reflect central MC4R activation in appetite-regulating neurons